

CAPTIONS TO SUPPLEMENTARY FIGURES




Figure S1. X-ray powder diffractograms (A) and differential scanning calorimetry thermograms (B) of pure crystalline olanzapine and samples containing crystalline olanzapine (formulation A) after physical mixture, incorporation of 40% of water, storage for 24 h, extrusion and spheronization (from bottom to the top) [coloration according to the drying temperature applied to samples: 40°C (dark blue), 65°C (purple) and 90°C (red)].




Figure S2. Fourier-transform mid (A) and near infrared spectra (B) of pure crystalline olanzapine (in blue) and after blending with the excipients described in Table 2 (formulation A, in orange).




Figure S3. Fourier-transform mid (A) and near infrared spectra (B) of formulations containing crystalline olanzapine (1, formulation A) or co-amorphous olanzapine (2, formulation B) after processing [from bottom to the top: after physical mixture, granulation, storage for 24 h, extrusion and spheronization (if applicable), coloration according to the drying temperature applied to samples: 40°C (dark blue), 65°C (purple) and 90°C (red)].